A Chicago jury ruled against an Illinois woman's claim that discontinued heartburn drug Zantac caused her colon cancer.
In a landmark trial, a Chicago jury sided with drugmakers GSK and Boehringer Ingelheim, rejecting an Illinois woman's claim that discontinued heartburn drug Zantac caused her colon cancer. Angela Valadez, the first plaintiff in thousands of similar lawsuits, argued that Zantac's active ingredient, ranitidine, can turn into a cancer-causing substance called NDMA under certain conditions. The jury agreed that Valadez failed to prove her cancer was at least partly caused by Zantac use, marking a significant win for the pharmaceutical industry in these cases.
May 22, 2024
13 Articles